MedWatch

Lundbeck faces criticism over new share structure

A new share structure is meant to beef up Lundbeck for future acquisitions, the company and its majority owner the Lundbeck Foundation say. The proposal has nevertheless been met with criticism from shareholders who fear dilution. On Wednesday, Lundbeck will meet its critics.

Lars Rasmussen, chair of the board of director at Lundbeck | Photo: Tycho Gregers/Ritzau/Ritzau Scanpix

A steadily decreasing share price and strong criticism from its base are the backdrop for Lundbeck’s annual general meeting on Wednesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs